The Life Sciences team advised I-Mab (Nasdaq: IMAB) on its strategic partnership with Kalbe Genexine Biologics (KG Bio), a joint venture of Kalbe Farma Tbk, and Genexine, Inc.
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. Kalbe Farma is one of the largest publically listed pharmaceutical companies in Southeast Asia. Genexine is a leading biotherapeutics company focused on immuno-oncology and orphan disease.
Under the terms of the agreement, KG Bio will receive a right of first negotiation for an exclusive license for the commercialization of two I-Mab discovered product candidates: TJD5, a highly differentiated anti-CD73 antibody in Phase 1 development for advanced solid tumors, and an I-Mab product candidate to be agreed upon by both parties. If and when I-Mab and KG Bio enter into the definitive licensing agreement for TJD5, I-Mab would be eligible to receive from KG Bio an aggregate amount of up to approximately $340 million, including an upfront payment and subsequent payments conditional upon achieving certain development and commercial milestones.